# Differentiated Thyroid Cancer: Post-Surgical I-131 Therapy ## Overview Differentiated thyroid cancer encompasses papillary carcinoma, which accounts for approximately 85% of cases, and follicular carcinoma, which accounts for about 10%. I-131 therapy after total thyroidectomy serves three distinct purposes: remnant ablation to destroy residual normal thyroid tissue, adjuvant therapy to eliminate suspected microscopic disease, and treatment of known residual or metastatic disease. The ATA risk stratification system determines which patients benefit from radioiodine therapy. ## ATA Risk Stratification ### Low Risk Low-risk patients have intrathyroidal DTC without vascular invasion, with complete surgical resection and no aggressive histologic features. This category includes classical papillary carcinoma, follicular variant, and encapsulated follicular carcinoma. Lymph node involvement is limited to five or fewer micrometastases smaller than 0.2 cm, and there is no RAI uptake outside the thyroid bed on the post-therapy scan. ### Intermediate Risk Intermediate-risk features include microscopic extrathyroidal extension, RAI-avid cervical lymph node metastases, aggressive histologic subtypes such as tall cell, hobnail, or columnar cell variants, and vascular invasion. Clinical N1 disease or more than five pathologic lymph nodes (all smaller than 3 cm) also places a patient in this category. ### High Risk High-risk patients have gross extrathyroidal extension with invasion of subcutaneous tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve. Incomplete tumor resection with gross residual disease, distant metastases, a postoperative thyroglobulin level suggestive of distant metastases, pathologic N1 disease with any lymph node 3 cm or larger, and follicular thyroid cancer with extensive vascular invasion (more than 4 foci) all qualify as high risk. ATA risk stratification system for differentiated thyroid cancer showing low, intermediate, and high-risk categories with corresponding I-131 therapy recommendations ## Indications for I-131 Therapy ### Remnant Ablation Remnant ablation destroys residual normal thyroid tissue remaining after total thyroidectomy. This facilitates thyroglobulin monitoring, since undetectable thyroglobulin after ablation indicates no residual or recurrent disease. It also allows subsequent diagnostic RAI whole-body scans to be interpretable by eliminating confounding remnant uptake. The role of remnant ablation in low-risk patients is controversial, with the ESTIMABL2 and IoN trials suggesting no benefit in recurrence-free survival for this group. ### Adjuvant Therapy Adjuvant therapy employs higher activities aimed at destroying suspected but unproven microscopic residual disease. It is indicated for intermediate-risk patients and may reduce recurrence rates. ### Treatment of Known Disease The highest activities are reserved for patients with known residual or metastatic disease, including locoregional lymph node metastases and pulmonary or bone metastases. RAI-avid distant metastases carry a better prognosis than RAI-refractory disease. ## Activity Selection ### Low-Risk (If RAI is Given) For remnant ablation in low-risk patients, 30 mCi (1.1 GBq) is sufficient. The ESTIMABL and HiLo trials demonstrated that 30 mCi is as effective as 100 mCi for remnant ablation in low-risk patients. ### Intermediate-Risk Activities range from 30 to 150 mCi (1.1 to 5.5 GBq), depending on the specific risk factors. Higher activities are used for aggressive histology, vascular invasion, or nodal disease. ### High-Risk Activities of 100 to 200 mCi (3.7 to 7.4 GBq) are used for known metastatic or residual disease. Dosimetry-guided therapy is considered for patients receiving repeated high-dose treatments or those with renal impairment. Blood-based dosimetry limits whole-body retention to less than 80 mCi at 48 hours and the blood dose to less than 200 cGy. | ATA Risk Category | Key Features | I-131 Activity | Goal | |---|---|---|---| | Low risk | Intrathyroidal, complete resection, no aggressive histology | 30 mCi (if given) or no RAI | Remnant ablation (controversial) | | Intermediate risk | Microscopic ETE, aggressive histology, N1 nodes | 30–150 mCi | Adjuvant therapy | | High risk | Gross ETE, incomplete resection, distant metastases | 100–200 mCi | Treatment of known disease | ## Pre-Therapy Preparation ### TSH Stimulation TSH must exceed 30 mIU/L to maximize sodium-iodide symporter expression and RAI uptake. Two methods are available. Thyroid hormone withdrawal involves stopping levothyroxine for 3 to 4 weeks, or switching to liothyronine for 2 weeks followed by 2 weeks off all thyroid hormone. Recombinant human TSH (Thyrogen) is administered as two intramuscular injections on consecutive days, with RAI given on day 3. Recombinant TSH avoids hypothyroid symptoms but is approved only for remnant ablation and diagnostic scanning in most guidelines, not for treatment of metastatic disease. ### Low-Iodine Diet Iodine intake is restricted to less than 50 mcg per day for 1 to 2 weeks before therapy. This depletes the body's iodine pool, increasing RAI uptake and the effective dose delivered to thyroid tissue. Patients must avoid iodized salt, dairy, seafood, egg yolks, and processed foods containing iodine-containing additives. ### Contraindications and Precautions Pregnancy and breastfeeding are absolute contraindications. A pregnancy test must be obtained within 72 hours of RAI administration. Recent iodinated contrast exposure requires a waiting period of 4 to 8 weeks, and urine iodine can be checked if there is uncertainty. Amiodarone produces iodine stores that may persist for months, generally rendering RAI therapy ineffective. Pre-therapy preparation timeline showing low-iodine diet initiation, thyroid hormone withdrawal schedule versus rhTSH protocol, and timing of I-131 administration ## Post-Therapy Whole-Body Scan A post-therapy whole-body scan is obtained 5 to 7 days after therapeutic I-131 administration. It evaluates the distribution of RAI, including thyroid bed uptake, cervical and mediastinal lymph node involvement, and distant metastases. The scan may reveal unsuspected metastases not identified on the pre-therapy diagnostic scan, which occurs in a meaningful minority of patients. No additional diagnostic dose is needed since the scan is performed with the therapeutic dose already administered. ## Side Effects and Complications ### Acute (Days to Weeks) Radiation sialadenitis involving the parotid and submandibular glands causes pain, swelling, and dry mouth. Prevention involves sialagogues such as sour candy or lemon drops starting 24 hours after RAI administration, along with good hydration. The optimal timing of sialagogues is debated, with some advocating a 24-hour delay to avoid increasing the salivary gland radiation dose. Other acute effects include nausea and mild gastrointestinal discomfort, transient taste changes (dysgeusia), and rarely, neck pain and swelling from radiation thyroiditis, which is uncommon after thyroidectomy. ### Subacute to Chronic Xerostomia, or chronic dry mouth, is a risk that increases with cumulative dose. Lacrimal gland dysfunction causing dry eyes or nasolacrimal duct obstruction is rare. Bone marrow suppression is transient and rarely clinically significant at standard doses. Pulmonary fibrosis is a risk in patients with diffuse pulmonary metastases receiving multiple high-dose treatments. ### Long-Term Risks A slight increased risk of second primary malignancies, specifically leukemia, salivary gland cancer, and bladder cancer, has been observed with cumulative doses exceeding 600 mCi. Gonadal effects include transient oligospermia in men, which recovers within 12 to 18 months, and no significant impact on female fertility at standard doses. Lifetime cumulative dose monitoring is important. ## Controversy: RAI in Low-Risk DTC ### ESTIMABL2 Trial This randomized trial compared RAI ablation with 30 mCi to no RAI after total thyroidectomy in low-risk patients. No significant difference in the rate of structural recurrence was found at 3 years, supporting the selective omission of RAI in truly low-risk patients. ### IoN Trial The IoN trial used a similar design and randomized low-risk DTC patients to RAI versus no RAI. Primary results suggest no benefit of RAI in low-risk patients, findings that may fundamentally change practice for low-risk DTC management. ### Current Practice ATA guidelines recommend against routine RAI for low-risk DTC. However, many centers still perform RAI ablation for intermediate-risk and selected low-risk patients. The decision should involve shared decision-making with the patient. Decision algorithm for I-131 therapy in differentiated thyroid cancer based on ATA risk stratification, showing the spectrum from observation (low risk) through high-dose treatment (high risk) ## Clinical Pearls Recombinant TSH preparation is preferred for remnant ablation because it avoids weeks of debilitating hypothyroidism. Low-iodine diet compliance significantly impacts therapy efficacy, and patients should receive detailed dietary instructions. The post-therapy scan is critical because it may reveal metastatic disease not previously known, changing the stage and follow-up plan. Sialagogues starting 24 hours after RAI, rather than immediately, may be the safest approach to prevent sialadenitis. Cumulative I-131 dose should be tracked, and dosimetry-guided therapy should be considered when approaching a 600 mCi lifetime dose. Thyroglobulin measured 6 to 12 months after RAI is the single most important prognostic marker for disease-free status. ## References - Haugen, B. R., et al. "2015 ATA Management Guidelines for DTC." *Thyroid*, 2016. - Mallick, U., et al. "HiLo Trial." *New England Journal of Medicine*, 2012. - Leboulleux, S., et al. "ESTIMABL2 Trial." *New England Journal of Medicine*, 2022. - Dehbi, H. M., et al. "IoN Trial." *New England Journal of Medicine*, 2022. - Tuttle, R. M., et al. "Dynamic Risk Stratification in DTC." *Endocrine Reviews*, 2010.